Wedbush Predicts Weaker Earnings for Oric Pharmaceuticals

Key Points

• Wedbush has lowered its Q3 2025 EPS estimate for Oric Pharmaceuticals to ($0.38), down from a prior estimate of ($0.36), while maintaining an "Outperform" rating with a price target of $20.00.
• Oric Pharmaceuticals reported a loss of ($0.47) EPS for the latest quarter, which was below analysts' expectations of ($0.46 EPS).
• Institutional investors hold approximately 95.05% of Oric Pharmaceuticals' stock, with significant recent activity including a 35.9% increase in holdings by Antipodes Partners Ltd.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Equities researchers at Wedbush lowered their Q3 2025 EPS estimates for shares of Oric Pharmaceuticals in a report issued on Tuesday, August 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.38) per share for the quarter, down from their prior estimate of ($0.36). Wedbush has a "Outperform" rating and a $20.00 price objective on the stock. The consensus estimate for Oric Pharmaceuticals' current full-year earnings is ($2.17) per share. Wedbush also issued estimates for Oric Pharmaceuticals' Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($1.68) EPS and FY2028 earnings at ($1.33) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01).

Several other brokerages have also recently issued reports on ORIC. Guggenheim reissued a "buy" rating and issued a $18.00 price objective on shares of Oric Pharmaceuticals in a report on Wednesday. JPMorgan Chase & Co. cut their price objective on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday. Cantor Fitzgerald reissued an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Zacks Research raised Oric Pharmaceuticals to a "hold" rating in a research note on Tuesday. Finally, HC Wainwright dropped their price target on shares of Oric Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Thursday. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.63.

Oric Pharmaceuticals Price Performance

ORIC stock opened at $9.93 on Friday. The company has a market capitalization of $964.40 million, a P/E ratio of -5.25 and a beta of 1.69. Oric Pharmaceuticals has a 12 month low of $3.90 and a 12 month high of $14.67. The firm's fifty day simple moving average is $10.29 and its 200-day simple moving average is $8.11.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Oric Pharmaceuticals by 2.9% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company's stock worth $497,000 after purchasing an additional 1,358 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its position in shares of Oric Pharmaceuticals by 35.9% during the second quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company's stock worth $53,000 after purchasing an additional 1,372 shares during the last quarter. Invesco Ltd. lifted its position in shares of Oric Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company's stock worth $193,000 after buying an additional 1,876 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Oric Pharmaceuticals by 17,300.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company's stock worth $25,000 after purchasing an additional 2,422 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in Oric Pharmaceuticals by 7.5% in the second quarter. Ameriprise Financial Inc. now owns 38,864 shares of the company's stock valued at $394,000 after buying an additional 2,706 shares during the last quarter. 95.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Angie You bought 26,597 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average cost of $9.39 per share, with a total value of $249,745.83. Following the purchase, the director directly owned 26,597 shares of the company's stock, valued at $249,745.83. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Dominic Piscitelli sold 32,466 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the transaction, the chief financial officer owned 68,317 shares of the company's stock, valued at approximately $717,328.50. The trade was a 32.21% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,000 shares of company stock valued at $416,289. 6.82% of the stock is currently owned by corporate insiders.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.